Evidence map›Paper›PMID 36233415›Full record

ArticleJournal of clinical medicine2022

Successful Treatment of Acute Uric Acid Nephropathy with Rasburicase in a Primary Central Nervous System Lymphoma Patient Showing a Dramatic Response to Methotrexate-Case Report.

Yoshihiro Mouri, Manabu Natsumeda, Noritaka Okubo, Taro Sato, Taiki Saito, Kohei Shibuya, Shiori Yamada, Jotaro On, Yoshihiro Tsukamoto, Masayasu Okada and 6 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Yoshihiro MouriDepartment of Neurosurgery, Brain Research Institute, Niigata University, Niigata 951-8585, Japan.
Manabu NatsumedaDepartment of Neurosurgery, Brain Research Institute, Niigata University, Niigata 951-8585, Japan.ORCID 0000-0003-3098-8323
Noritaka OkuboDepartment of Neurosurgery, Brain Research Institute, Niigata University, Niigata 951-8585, Japan.
Taro SatoDepartment of Neurosurgery, Brain Research Institute, Niigata University, Niigata 951-8585, Japan.
Taiki SaitoDepartment of Neurosurgery, Brain Research Institute, Niigata University, Niigata 951-8585, Japan.
Kohei ShibuyaDepartment of Neurosurgery, Brain Research Institute, Niigata University, Niigata 951-8585, Japan.
Shiori YamadaDepartment of Neurosurgery, Brain Research Institute, Niigata University, Niigata 951-8585, Japan.
Jotaro OnDepartment of Neurosurgery, Brain Research Institute, Niigata University, Niigata 951-8585, Japan.ORCID 0000-0001-5887-7153
Yoshihiro TsukamotoDepartment of Neurosurgery, Brain Research Institute, Niigata University, Niigata 951-8585, Japan.
Masayasu OkadaDepartment of Neurosurgery, Brain Research Institute, Niigata University, Niigata 951-8585, Japan.ORCID 0000-0002-9151-8184
Makoto OishiDepartment of Neurosurgery, Brain Research Institute, Niigata University, Niigata 951-8585, Japan.
Takeyoshi EdaDivision of Pharmacy, Medical and Dental Hospital, Niigata University, Niigata 951-8520, Japan.
Junko MuraiInstitute for Advanced Biosciences, Keio University, Tsuruoka 997-0052, Japan.
Hiroshi ShimizuDepartment of Pathology, Brain Research Institute, Niigata University, Niigata 951-8585, Japan.
Akiyoshi KakitaDepartment of Pathology, Brain Research Institute, Niigata University, Niigata 951-8585, Japan.ORCID 0000-0003-4244-0277
Yukihiko FujiiDepartment of Neurosurgery, Brain Research Institute, Niigata University, Niigata 951-8585, Japan.
Niigata University · JPKeio University · JPNiigata University Medical and Dental Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrimary central nervous system lymphomas (PCNSLs) are sensitive to chemotherapy. The standard treatment is high-dose methotrexate (MTX)-based chemotherapy. There are no reports of successful treatment of acute uric acid nephropathy with rasburicase after MTX administration in PCNSLs. CASE PRESENTATION: A 54-year-old man with a history of gout presented with a change in character and cognitive dysfunction. MRI showed a large enhancing mass spanning the bilateral frontal lobes and the right temporal lobe. After endoscopic biopsy, an MTX, procarbazine, and vincristine (MPV) regimen was initiated for the treatment of the PCNSL. After the initiation of chemotherapy, the patient experienced a gout attack, and blood examination revealed acute renal failure (ARF) and hyperuricemia. The considered causes of ARF included MTX toxicity and acute uric acid nephropathy. As the dramatic effect of MTX was observed, treatment was continued despite ARF, most probably due to acute hyperuricemia due to tumor lysis, which was treated in parallel. After an improvement in renal function, MTX was resumed, and rasburicase was initiated to control hyperuricemia. A complete response was obtained after induction chemotherapy. Hyperuricemia was controlled with rasburicase, and renal function was preserved.

conclusionsAcute uric acid nephropathy should be considered when ARF occurs after the initiation of MTX in PCNSLs, especially in newly diagnosed PCNSL patients with large tumors or hyperuricemia.

Indexed as

acute uric acid nephropathyhigh-dose methotrexatePCNSLsrasburicase

Identifiers

PMID36233415
PMCPMC9571497
OpenAlexW4296617448

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.